Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-Term Adaptive Radiotherapy with Intratumoral High-Dose Boost for Head and Neck Cancer
jRCTs011250001Recruiting
- Sponsor
- Hokkaido University Hospital
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of cisplatin in oropharyngeal squamous cell carcinoma (OPSCC), squamous cell carcinoma of the hypopharynx and laryngeal squamous cell carcinoma (LSCC), sponsored by Hokkaido University Hospital. Primary endpoints: Dose Limiting Toxicity (DLT) and Overall survival rate. Started Apr 2025; status: recruiting.
02
Drugs
cisplatin
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)squamous cell carcinoma of the hypopharynxlaryngeal squamous cell carcinoma (LSCC)
Beyond the preview
Go deeper on jRCTs011250001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs011250001.